BCL2 and ovarian cancer: Further experiments indicated navitoclax but not venetoclax could also sensitize OVCAR8 cells to paclitaxel-induced apoptosis (Fig. 6g, h), in agreement with the results that most ovarian cancer cells have abundant BCLXL, but not BCL2 (Fig. 4c).